Clinical Trial Update: AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing AG versus mFOLFIRINOX as neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer
• Pancreatic Adenocarcinoma

Drugs mentioned

• AG
• mFOLFIRINOX

Snippet

Sponsor: Fudan University | Conditions: Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | Status: UNKNOWN